Welcome to our dedicated page for Palatin Tech news (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Tech stock.
Palatin Technologies, Inc. (PTN) generates a steady flow of news as a biopharmaceutical company centered on melanocortin receptor–based therapeutics. News coverage for PTN often highlights updates on its obesity, ocular, and retinal programs, as well as financing events and stock listing developments. Investors and followers can use this page to review how Palatin’s scientific, clinical, and corporate milestones evolve over time.
Recent press releases have focused on obesity program progress, including preclinical and clinical data for the oral MC4R agonist PL7737 and next-generation peptide MC4R agonists. Palatin has reported robust weight loss and favorable safety in preclinical models, Phase 2 data on co-administration of an MC4R agonist with tirzepatide in obese patients, and regulatory designations such as Orphan Drug status for PL7737 in LEPR deficiency–related obesity. These updates provide insight into the company’s efforts to develop mechanism-based obesity therapies.
Palatin news also covers its ocular and retinal pipeline. Releases describe Phase 3 MELODY-1 data for PL9643 in dry eye disease, including responder analyses showing complete symptom resolution across multiple endpoints, and preclinical findings for PL9654 and PL9655 in diabetic retinopathy that demonstrate inflammation resolution, vascular stabilization, and neuroprotection. Announcements related to the company’s collaboration with Boehringer Ingelheim for retinal diseases further illustrate how Palatin seeks to advance its melanocortin platform through partnerships.
On the corporate side, PTN news items detail public offerings, warrant structures, and exchange listing status, including NYSE American delisting proceedings, trading on OTC markets, a 1-for-50 reverse stock split, and the subsequent resumption of trading on NYSE American. For readers tracking PTN, this news feed brings together scientific presentations, clinical trial readouts, collaboration agreements, and capital markets activity in one place, making it easier to follow Palatin’s development trajectory and key disclosures.
Palatin Technologies (NYSE American: PTN) presented new preclinical data for PL9588, their novel melanocortin receptor agonist, at the 2025 ARVO Annual Meeting. The data demonstrates PL9588's potential as a dual-action glaucoma therapy that both reduces intraocular pressure (IOP) and provides neuroprotection.
Key findings show that PL9588 increases fluid movement through the trabecular meshwork (p0.05) and reduces retinal cell stress/death by ~25% in damaged retinas (p<0.05). The compound also decreased retinal ganglion cell death in an ischemia/reperfusion model (p<0.0001).The global glaucoma market, valued at $5.71 billion in 2021, is projected to reach $9.77 billion by 2030. Glaucoma affects approximately 79.6 million people worldwide (2020) and is a leading cause of preventable vision loss.
Palatin Technologies announced breakthrough results from its Phase 3 MELODY-1 clinical trial for PL9643 in treating dry eye disease (DED). The drug achieved statistically significant complete symptom resolution across multiple endpoints - a first among dry eye therapies.
Key highlights:
- 6 out of 13 symptom endpoints showed significantly higher patient recovery with PL9643 vs placebo
- Symptom improvement started at week 2 and continued through week 12
- Treatment demonstrated better results than any FDA-approved DED therapy
- The drug showed excellent safety and tolerability
The company plans to conduct two more Phase 3 studies (MELODY-2 and MELODY-3) pending collaboration and funding. The dry eye disease market is projected to grow from $6.11 billion in 2024 to $7.46 billion by 2029. With 38 million Americans affected by DED but only 10% receiving prescription treatment, PL9643 represents a significant market opportunity.
Palatin Technologies (NYSE American: PTN) has announced positive appetite suppression results from its BMT-801 Phase 2 obesity study evaluating the co-administration of melanocortin 4 receptor (MC4R) agonist bremelanotide with GLP-1/GIP tirzepatide.
Key findings show significant improvements in appetite suppression across all treatment arms:
- Bremelanotide + tirzepatide: 71% increase
- Tirzepatide only: 73% increase
- Bremelanotide only: 71% increase
Notably, low-dose bremelanotide demonstrated effectiveness in preventing weight regain after tirzepatide discontinuation, while patients on tirzepatide alone regained over 50% of lost weight within two weeks of stopping treatment. The company plans to advance its next-generation MC4R agonists pipeline, with IND filings expected by Q4 2025 and initial clinical data in H1 2026.
Palatin Technologies (NYSE American: PTN) has formally appealed NYSE Regulation's determination to delist its common stock after failing to meet stockholders' equity requirements by April 10, 2025. The company's stock will continue trading during the 60-to-90-day appeal process.
To regain compliance, Palatin is implementing a financial strengthening plan that includes:
- Accelerating out-licensing discussions
- Advancing equity financing negotiations
- Exploring strategic funding opportunities
CEO Carl Spana expressed confidence in the company's ability to address listing requirements, though success of the appeal cannot be guaranteed. The final decision on whether PTN remains listed will be determined by the NYSE Listings Qualifications Panel.
Palatin Technologies (NYSE American:PTN) announced on April 10, 2024, that NYSE American has initiated delisting proceedings for the company's common stock. The decision comes after PTN failed to regain compliance with stockholders' equity requirements under Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide by the end of its 18-month compliance period on April 10, 2025.
The company has until April 25, 2025, to request a review of the delisting determination by the Listings Qualifications Panel. PTN has confirmed its intention to appeal the decision and expects its common stock to continue trading on NYSE American during the appeal process. While the company is working to regain compliance, there is no guarantee of success before any hearing occurs.
Palatin Technologies (NYSE American: PTN) announced positive Phase 2b BREAKOUT study results for their melanocortin agonist treatment in Type 2 diabetic nephropathy patients. The six-month open-label study demonstrated significant improvements in kidney function:
- 71% of patients achieved >30% reduction in urine protein to creatinine ratio (UP/Cr)
- 71% showed improved or stabilized estimated glomerular filtration rate (eGFR)
- 37.5% experienced increased urinary VEGF levels
- 36% demonstrated reduced urinary synaptopodin loss
The study enrolled 16 patients with confirmed Type 2 diabetic nephropathy and >1000 mg/gm UP/Cr ratio, with 8 completing the six-month treatment. The treatment involved subcutaneous bremelanotide administration twice daily alongside maximum tolerated RAAS inhibition therapy.
Palatin Technologies (NYSE: PTN) announced positive results from its Phase 2 obesity study combining MC4R agonist bremelanotide with GLP-1/GIP tirzepatide. The 8-week treatment study met its primary endpoint with highly statistically significant results.
Key findings include:
- Co-administered group showed 4.4% weight reduction vs 1.6% for placebo (p0.0001)40% of co-administered patients achieved 5% weight reduction
- 27% reached 6% weight reduction
- 19% achieved 7% weight reduction
The study involved 113 patients, with 96 randomized across four treatment groups. Low-dose bremelanotide effectively stopped weight regain post-tirzepatide treatment. The company plans IND applications for next-generation MC4R long-acting peptides and oral small molecules in Q4 2025, with clinical data expected in 1H 2026.
Palatin Technologies (NYSE: PTN) has announced positive topline results from its Phase 2 study of PL8177, an oral melanocortin-1 receptor agonist, for treating ulcerative colitis (UC). The study demonstrated significant efficacy after eight weeks of treatment:
Key findings include:
- Clinical remission achieved in 33% of PL8177-treated patients vs 0% on placebo
- Clinical response shown in 78% of PL8177-treated patients vs 33% on placebo (p0.005)Symptomatic remission reached in 56% of PL8177-treated patients vs 33% on placebo
The trial involved 12 patients (9 PL8177, 3 placebo) with active UC. The treatment demonstrated excellent safety with no adverse events reported. In patients with moderate disease affecting all three colon segments, 60% showed improvement across all segments, and 80% improved in two segments. The company is currently in licensing discussions with multiple pharmaceutical companies.